Masterflex SE (ISIN: DE0005492938) announced preliminary figures for the 2025 financial year, meeting its forecast and achieving new record earnings despite a challenging economic environment. Group revenue rose 4.6% to EUR 102.6 million from EUR 98.1 million in the previous year, within the forecast range of EUR 100 million to EUR 105 million. Operating EBITDA increased by 7.4% to a record EUR 19.5 million, while operating EBIT grew by 9.8% to EUR 14.0 million, also a new record. EBIT rose 9.2% to EUR 13.7 million, within the forecast of EUR 12 million to EUR 15 million.
The US subgroup and medical technology segment were key growth drivers. Medical technology's share of consolidated revenue increased from 18% in 2024 to 21% in 2025, reflecting dynamic demand. In contrast, demand in the industrial 'Tech' sector and trading business declined moderately, particularly in Germany. The order backlog remained stable at EUR 19.8 million, consistent with the previous year.
Despite currency losses and start-up costs for a new site in Morocco, the operating EBIT margin improved to 13.6% from 13.0% in the prior year. Masterflex also strengthened its financial position, with the equity ratio rising to 73.3% from 67.7% and net debt falling sharply to EUR 2.7 million from EUR 9.0 million. The debt ratio (net debt/EBITDA) improved to 0.1 from 0.5.
CEO Dr Andreas Bastin commented: 'Despite a continuing challenging economic environment, we met our forecasts in the 2025 financial year, achieved solid revenue growth and slightly increased our profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing.'
The figures are preliminary and subject to confirmation by auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and 2026 forecast will be published on March 31, 2026. More details about Masterflex SE can be found on their website at Cross Alliance.


